Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline

Journal of Clinical Oncology

Volumn 34, Issue 27, 2016, Pages 3325-3345

  Paice, Judith A ^a   Portenoy, Russell ^b   Lacchetti, Christina ^f   Campbell, Toby ^g   Cheville, Andrea ^h   Citron, Marc ^d   Constine, Louis S ^e   Cooper, Andrea ⁱ   Glare, Paul ^c   Keefe, Frank ^j   Koyyalagunta, Lakshmi ^k   Levy, Michael ^l   Miaskowski, Christine ^m   Otis Green, Shirley ⁿ   Sloan, Paul ^o   Bruera, Eduardo ^k  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MJHS Institute for Innovation in Palliative Care   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d ProHEALTH Care Associates LLP   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

^h MAYO CLINIC   (United States)

ⁱ MERCY MEDICAL CENTER   (United States)

^j DUKE UNIVERSITY   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l FOX CHASE CANCER CENTER   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ Coalition for Compassionate Care of California ^*  (United States)

^o UNIVERSITY OF KENTUCKY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; OPIATE;

ADULT; AMENORRHEA AND OLIGOMENORRHEA; ANALGESIA; ARTICLE; BLOATING; CANCER PAIN; CANCER SURVIVOR; CHRONIC DISEASE; CHRONIC PAIN; CONSENSUS; CONSTIPATION; DOCTOR PATIENT RELATION; DRUG MISUSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; FATIGUE; FUNCTIONAL STATUS; HEALTH DISPARITY; HEARTBURN; HUMAN; HYPERALGESIA; HYPERPROLACTINEMIA; HYPOGONADISM; INFERTILITY; INTEGRATIVE MEDICINE; INTERVENTION STUDY; LIBIDO DISORDER; MEDICAL EXPERT; MEDICAL INFORMATION; MEDICAL SOCIETY; MENTAL DISEASE; META ANALYSIS (TOPIC); MYOCLONUS; NAUSEA; NEUROTOXICITY; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PAIN INTENSITY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION MEDICINE; RISK ASSESSMENT; SCREENING; SLEEP DISORDERED BREATHING; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION; UNIVERSAL PRECAUTION; PROCEDURES;

CANCER PAIN; CHRONIC PAIN; HUMANS; PAIN MANAGEMENT;

EID: 84990046451     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.5206     Document Type: Article

References (115)

1. US Cancer Statistics Working Group: United States Cancer Statistics: 1999-2012 Incidence and Mortality Web-Based Report. Atlanta, GA, US Department of Health and Human Services. http://ww.cdc.gov/uscs
2. Henley SJ, Singh SD, King J, et al: Invasive cancer incidence and survival - United States, 2012. MMWR Morb Mortal Wkly Rep 64:1353-1358, 2015
3. Jensen MP, Chang HY, Lai YH, et al: Pain in long-term breast cancer survivors: Frequency, severity, and impact. Pain Med 11:1099-1106, 2010
4. Davidsen M, Kjøller M, Helweg-Larsen K: The Danish National Cohort Study (DANCOS). Scand J Public Health 39:131-135, 2011 (suppl 7)
5. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, et al: Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. J Pain Symptom Manage 51:1070-1090, 2016
6. Green CR,Hart-Johnson T,Loeffler DR: Cancer-related chronic pain: Examining quality of life in diverse cancer survivors. Cancer 117:1994-2003, 2011
7. WHO. Cancer Pain Relief (ed 2). Geneva, Switzerland, WHO, 1996
8. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain, Volume 2. 2016. www.nccn.org
9. Glare PA, Davies PS, Finlay E, et al: Pain in cancer survivors. J Clin Oncol 32:1739-1747, 2014
10. Portenoy RK, Ahmed E: Principles of opioid use in cancer pain. J Clin Oncol 32:1662-1670, 2014
11. Shiffman RN, Michel G, Rosenfeld RM, et al: Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc 19:94-101, 2012
12. Shea BJ, Grimshaw JM, Wells GA, et al: Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 7:10, 2007
13. Jongen JL, Huijsman ML, Jessurun J, et al: The evidence for pharmacologic treatment of neuropathic cancer pain: Beneficial and adverse effects. J Pain Symptom Manage 46:581-590 e1, 2013
14. Koyyalagunta D, Bruera E, Solanki DR, et al: A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 15:ES39-ES58, 2012 (suppl 3)
15. Riemsma R, Forbes C, Harker J, et al: Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 27:1907-1930, 2011
16. Pigni A, Brunelli C, Caraceni A: The role of hydromorphone in cancer pain treatment: A systematic review. Palliat Med 25:471-477, 2011
17. King SJ, Reid C, Forbes K, et al: A systematic review of oxycodone in the management of cancer pain. Palliat Med 25:454-470, 2011
18. Mayyas F, Fayers P, Kaasa S, et al: A systematic review of oxymorphone in the management of chronic pain. J Pain Symptom Manage 39:296-308, 2010
19. Ahmedzai SH, Nauck F, Bar-Sela G, et al: A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 26:50-60, 2012
20. Moore RA, Wiffen PJ, Derry S, et al: Gabapentin for chronic neuropathic painand fibromyalgia in adults. Cochrane Database Syst Rev (3):CD007938, 2011
21. Bennett MI: Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: Systematic review. Palliat Med 25:553-559, 2011
22. Finnerup NB, Sindrup SH, Jensen TS: The evidence for pharmacological treatment of neuropathic pain. Pain 150:573-581, 2010
23. Saarto T, Wiffen PJ: Antidepressants for neuropathic pain: A Cochrane review. J Neurol Neurosurg Psychiatry 81:1372-1373, 2010
24. Bredlau AL, Thakur R, Korones DN, et al: Ketamine for pain in adults and children with cancer: A systematic review and synthesis of the literature. Pain Med 14:1505-1517, 2013
25. Bell RF, Eccleston C, Kalso EA: Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 11:CD003351, 2012
26. Paulsen Ø, Aass N, Kaasa S, et al: Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. J Pain Symptom Manage 46:96-105, 2013
27. Nabal M, Librada S, Redondo MJ, et al: The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliat Med 26:305-312, 2012
28. Derry S, Sven-Rice A, Cole P, et al: Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2:CD007393, 2013
29. Lynch ME, Ware MA: Cannabinoids for the treatment of chronic non-cancer pain: An updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol 10:293-301, 2015
30. Whiting PF, Wolff RF, Deshpande S, et al: Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 313:2456-2473, 2015
31. Andreae MH, Carter GM, Shaparin N, et al: Inhaled cannabis for chronic neuropathic pain: A meta-analysis of individual patient data. J Pain 16:1221-1232, 2015
32. Lynch ME, Campbell F: Cannabinoids for treatment of chronic non-cancer pain; A systematic review of randomized trials. Br J Clin Pharmacol 72:735-744, 2011
33. Campbell FA, Tramèr MR, Carroll D, et al: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:13-16, 2001
34. Johnson JR, Burnell-Nugent M, Lossignol D, et al: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39:167-179, 2010
35. Ware MA, Wang T, Shapiro S, et al: Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain 16:1233-1242, 2015
36. Mishra SI, Scherer RW, Geigle PM, et al: Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev 8:CD007566, 2012
37. Fong DY, Ho JW, Hui BP, et al: Physical activity for cancer survivors: Meta-analysis of randomised controlled trials. BMJ 344:e70, 2012
38. Cantarero-Villanueva I, Fernández-Lao C, Fernández-de-Las-Peñas C, et al: Effectiveness of water physical therapy on pain, pressure pain sensitivity, and myofascial trigger points in breast cancer survivors: A randomized, controlled clinical trial. Pain Med 13:1509-1519, 2012
39. Fernández-Lao C, Cantarero-Villanueva I, Fernández-de-Las-Peñas C, et al: Effectiveness of a multidimensional physical therapy program on pain, pressure hypersensitivity, and trigger points in breast cancer survivors: A randomized controlled clinical trial. Clin J Pain 28:113-121, 2012
40. May AM, Korstjens I, van Weert E, et al: Long-term effects on cancer survivors' quality of life of physical training versus physical training combined with cognitive-behavioral therapy: Results from a randomized trial. Support Care Cancer 17:653-663, 2009
41. Paley CA, Johnson MI, Tashani OA, et al: Acupuncture for cancer pain in adults. Cochrane Database Syst Rev 10:CD007753, 2015
42. Garcia MK, McQuade J, Haddad R, et al: Systematic review of acupuncture in cancer care: A synthesis of the evidence. J Clin Oncol 31:952-960, 2013
43. Choi TY, Lee MS, Kim TH, et al: Acupuncture for the treatment of cancer pain: A systematic review of randomised clinical trials. Support Care Cancer 20:1147-1158, 2012
44. Lee SH, Kim JY, Yeo S, et al: Meta-analysis of massage therapy on cancer pain. Integr Cancer Ther 14:297-304, 2015
45. Kwekkeboom KL, Cherwin CH, Lee JW, et al: Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. J Pain Symptom Manage 39:126-138, 2010
46. Arcidiacono PG, Calori G, Carrara S, et al: Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev (3):CD007519, 2011
47. Karmakar MK, Samy W, Li JW, et al: Thoracic paravertebral block and its effects on chronic pain and health-related quality of life after modified radical mastectomy. Reg Anesth Pain Med 39:289-298, 2014
48. Berenson J, Pflugmacher R, Jarzem P, et al: Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol 12:225-235, 2011
49. Fourney DR, Schomer DF, Nader R, et al: Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg 98(1, Suppl)21-30, 2003
50. Thimineur MA, Kravitz E, Vodapally MS. Intrathecal opioid treatment for chronic non-malignant pain: A 3-year prospective study. Pain 109:242-249, 2004
51. Smith TJ, Staats PS, Deer T, et al: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol 20:4040-4049, 2002
52. Johannsen M, Farver I, Beck N, et al: The efficacy of psychosocial intervention for pain in breast cancer patients and survivors: A systematic review and meta-analysis. Breast Cancer Res Treat 138:675-690, 2013
53. Sheinfeld Gorin S, Krebs P, Badr H, et al: Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol 30:539-547, 2012
54. Veehof MM, Oskam MJ, Schreurs KM, et al: Acceptance-based interventions for the treatment of chronic pain: A systematic review and meta-analysis. Pain 152:533-542, 2011
55. Cramer H, Lauche R, Paul A, et al: Hypnosis in breast cancer care: A systematic review of randomized controlled trials. Integr Cancer Ther 14:5-15, 2015
56. Matchim Y, Armer JM, Stewart BR: Mindfulness-based stress reduction among breast cancer survivors: A literature review and discussion. Oncol Nurs Forum 38:E61-E71, 2011
57. Hurlow A, Bennett MI, Robb KA, et al: Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev 3:CD006276, 2012
58. Wilkie G, Sakr B, Rizack T: Medical marijuana use in oncology: A review. JAMA Oncol. [epub ahead of print on Mar 17, 2017] doi:10.1001/jamaoncol.2016.0155
59. Kramer JL: Medical marijuana for cancer. CA Cancer J Clin 65:109-122, 2015
60. Portenoy RK: Treatment of cancer pain. Lancet 377:2236-2247, 2011
61. Dev R, Hui D, Del Fabbro E, et al: Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer. Cancer 120:1586-1593, 2014
62. Correa D, Farney RJ, Chung F, et al: Chronic opioid use and central sleep apnea: A review of the prevalence, mechanisms, and perioperative considerations. Anesth Analg 120:1273-1285, 2015
63. Lee M, Silverman SM, Hansen H, et al: A comprehensive review of opioid-induced hyperalgesia. Pain Physician 14:145-161, 2011
64. Sacerdote P, Franchi S, Panerai AE: Nonanalgesic effects of opioids: Mechanisms and potential clinical relevance of opioid-induced immunodepression. Curr Pharm Des 18:6034-6042, 2012
65. Ninković J, Roy S: Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids 45:9-24, 2013
66. Lennon FE MT, Mirzapoiazova T, Mambetsariev B, et al: The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One 9:e91577, 2014
67. Gupta K, Kshirsagar S, Chang L, et al: Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62:4491-4498, 2002
68. Gong L, Dong C, Ouyang W, et al: Regulatory T cells: A possible promising approach to cancer recurrence induced by morphine. Med Hypotheses 80:308-310, 2013
69. Shakeri R, Malekzadeh R, Etemadi A, et al: Opium: An emerging risk factor for gastric adenocarcinoma. Int J Cancer 133:455-461, 2013
70. Manchikanti L, Abdi S, Atluri S, et al: American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I-evidence assessment. Pain Physician 15(3, Suppl)S1-S65, 2012
71. Gourlay DL, Heit HA, Almahrezi A: Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 6:107-112, 2005
72. Butler SF, Budman SH, Fernandez K, et al: Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 112:65-75, 2004
73. Butler SF, Fernandez K, Benoit C, et al: Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain 9:360-372, 2008
74. Butler SF, Budman SH, Fernandez KC, et al: Development and validation of the Current Opioid Misuse Measure. Pain 130:144-156, 2007
75. Webster LR, Webster RM: Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Med 6:432-442, 2005
76. Jones T, Moore T: Preliminary data on a new opioid risk assessment measure: The Brief Risk Interview. J Opioid Manag 9:19-27, 2013
77. Jones T, Lookatch S, Moore T: Validation of a new risk assessment tool: The Brief Risk Questionnaire. J Opioid Manag 11:171-183, 2015
78. Boscarino JA, Rukstalis M, Hoffman SN, et al: Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 105:1776-1782, 2010
79. Liebschutz JM, Saitz R, Weiss RD, et al: Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. J Pain 11:1047-1055, 2010
80. White AG, Birnbaum HG, Schiller M, et al: Analytic models to identify patients at risk for prescription opioid abuse. Am J Manag Care 15:897-906, 2009
81. Manchikanti L, Manchukonda R, Damron KS, et al: Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician 9:57-60, 2006
82. Wang J, Christo PJ: The influence of prescription monitoring programs on chronic pain management. Pain Physician 12:507-515, 2009
83. Reifler LM, Droz D, Bailey JE, et al: Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med 13:434-442, 2012
84. Gugelmann HM, Perrone J: Can prescription drug monitoring programs help limit opioid abuse? JAMA 306:2258-2259, 2011
85. Paulozzi LJ, Kilbourne EM, Desai HA: Prescription drug monitoring programs and death rates from drug overdose. Pain Med 12:747-754, 2011
86. Manchikanti L, Hirsch JA, Smith HS: Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: Part 2: Randomized controlled trials. Pain Physician 11:717-773, 2008
87. Starrels JL, Becker WC, Alford DP, et al: Systematic review: Treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med 152:712-720, 2010
88. Dowell D, Haegerich TM, Chou R: CDc guideline for prescribing opioids for chronic pain - United States, 2016. JAMA 315:1624-1645, 2016
89. Chou R, Fanciullo GJ, Fine PG, et al: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10:113-130, 2009
90. Berna C, Kulich RJ, Rathmell JP: Tapering long-term opioid therapy in chronic noncancer pain: Evidence and recommendations for everyday practice. Mayo Clin Proc 90:828-842, 2015
91. Hershman DL, Lacchetti C, Dworkin RH, et al: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941-1967, 2014
92. Siegal T, Haim N: Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 66:1117-1123, 1990
93. Syrjala KL, Langer SL, Abrams JR, et al: Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 23:6596-6606, 2005
94. Cirrone F, Harris CS: Vismodegib and the hedgehog pathway: A new treatment for basal cell carcinoma. Clin Ther 34:2039-2050, 2012
95. Syrjala KL, Yi JC, Artherholt SB, et al: Measuring musculoskeletal symptoms in cancer survivors who receive hematopoietic cell transplantation. J Cancer Surviv 4:225-235, 2010
96. Söderberg Löfdal KC, Andersson ML, Gustafsson LL: Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. Drugs 73:533-543, 2013
97. Samer CF, Daali Y, Wagner M, et al: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160:907-918, 2010
98. Overholser BR, Foster DR: Opioid pharmacokinetic drug-drug interactions. Am J Manag Care 17(Suppl 11):S276-S287, 2011
99. Kapur BM, Hutson JR, Chibber T, et al: Methadone: A review of drug-drug and pathophysiological interactions. Crit Rev Clin Lab Sci 48:171-195, 2011
100. Keller GA, Ponte ML, Di Girolamo G: Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf 5:105-111, 2010
101. Singleton PA, Moss J, Karp DD, et al: The mu opioid receptor: A new target for cancer therapy? Cancer 121:2681-2688, 2015
102. Dart RC, Surratt HL, Cicero TJ, et al: Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 372:241-248, 2015
103. Reddy A, de la Cruz M, Rodriguez EM, et al: Patterns of storage, use, and disposal of opioids among cancer outpatients. Oncologist 19:780-785, 2014
104. Alford DP: Opioid prescribing for chronic pain-achieving the right balance through education. N Engl J Med 374:301-303, 2016
105. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, The Commonwealth Fund, 2008
106. Green CR, Anderson KO, Baker TA, et al: : The unequal burden of pain: Confronting racial and ethnic disparities in pain. Pain Med 4:277-294, 2003
107. [Erratum Green CR, Anderson KO, Baker TA, et al: The unequal burden of pain: Confronting racial and ethnic disparities in pain. Pain Med 6:99, 2005] doi:10.1046/j.1526-4637.2003.03034.x
108. Mossey JM: Defining racial and ethnic disparities in pain management. Clin Orthop Relat Res 469:1859-1870, 2011
109. Hausmann LR, Gao S, Lee ES, et al: Racial disparities in the monitoring of patients on chronic opioid therapy. Pain 154:46-52, 2013
110. Shavers VL, Bakos A, Sheppard VB: Race, ethnicity, and pain among the U.S. adult population. J Health Care Poor Underserved 21:177-220, 2010
111. Chen I, Kurz J, Pasanen M, et al: Racial differences in opioid use for chronic nonmalignant pain. J Gen Intern Med 20:593-598, 2005
112. Chang KL, Fillingim R, Hurley RW, et al: Chronic pain management: Nonpharmacological therapies for chronic pain. FP Essent 432:21-26, 2015
113. Howe CQ, Sullivan MD: The missing 'P' in pain management: How the current opioid epidemic highlights the need for psychiatric services in chronic pain care. Gen Hosp Psychiatry 36:99-104, 2014
114. Workman EA, Hubbard JR, Felker BL: Comorbid psychiatric disorders and predictors of pain management program success in patients with chronic pain. Prim Care Companion J Clin Psychiatry 4:137-140, 2002
115. Taylor ML:The impact of the "business" of pain medicine on patient care. Pain Med 12:763-772, 2011